Skip to main content
Lantus® (insulin glargine) injection 100 Units/mL logo

Lantus® (insulin glargine) injection 100 Units/mL Resources For Your Patients


"Sanofi Patient Support" with Learn More call-to-action button featuring older couple listening to a younger woman in the background.

Lantus® (insulin glargine) injection 100 Units/mL Resources For Your Patients

Sanofi Patient Connection®

Patient assistance designed to help provide certain Sanofi prescription medications at no cost for those who meet program eligibility requirements

Lantus SoloStar® pen injection for your patients

How to use the Lantus SoloStar pen.

Rotate injection sites from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into affected areas.

Icon with yellow dollar in a blue circle.

Lantus Savings Offers

Commercially insured patients pay no more than $35* per 30-day supply. Your uninsured or insured patients who prefer to pay cash outside of their prescription drug benefit will pay $35* per 30-day supply of any one or combination of Sanofi Insulins. *See Terms and Eligibility Restrictions

Icon of hand holding an insulin pen in a blue circle.

If your patients are controlled on Lantus

Keep them on Lantus

   

Important Safety Information

Important Safety Information for Lantus (insulin glargine injection) 100 Units/mL

Contraindications
Lantus is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin glargine or any of the excipients in LANTUS.

Warnings and Precautions
Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles.
Monitor blood glucose in all patients treated with insulin. Modify insulin regimen only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant drugs.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Do not dilute or mix Lantus with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus via an insulin pump or intravenously because severe hypoglycemia can occur.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus, and may be life-threatening.

Hypoglycemia due to medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus, treat and monitor until symptoms resolve.

A reduction in the Lantus dose may be required in patients with renal or hepatic impairment.

As with all insulins, Lantus use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions
Adverse reactions commonly associated with Lantus include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus SoloSTAR

Lantus SoloSTAR is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen: otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Click here for Full Prescribing Information for Lantus.

Click here for information on Sharps Medical Waste Disposal.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Indication

Indication and Use
LANTUS is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Limitations of Use
Lantus is not recommended for the treatment of diabetic ketoacidosis.

Important Safety Information

Indication

LANTUS, TOUJEO, TOUJEO Max SoloStar, SOLIQUA, SoloStar and Sanofi are registered trademarks of Sanofi or an affiliate. All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi. MAT-US-2006925-v6.0-11/2025